PharmaSGP Holding Surpasses €100M Revenue in 2023, Eyes More Profit Growth in 2024

• PharmaSGP Holding SE exceeded the €100 million revenue mark for the first time in 2023, reaching €101.1 million based on preliminary, unaudited figures.
• The increase in revenues of 17.8% compared to the prior-year period (€85.8 million) is due to strong organic growth achieved by PharmaSGP.
• Adjusted earnings before interest, taxes, depreciation and amortization (adjusted EBITDA) amounted to €34.1 million in 2023, an increase of 20.8% compared to the previous year (€28.2 million).
• Both revenues and adjusted EBITDA are slightly above the 2023 forecast.
• For the 2024 financial year, the Management Board of PharmaSGP expects revenues between €107.0 million and €112.0 million and adjusted EBITDA between €35.0 million and €38.0 million.
• PharmaSGP will publish its full annual report for 2023 on 29 April, 2024.

The price of PharmaSGP Holding at the time of the news was 22,600EUR and did not change compared to the previous day.
19 minutes after the article was published, the price was 22,800EUR this corresponds to a plus of +0,88 % since publication.

PharmaSGP Holding

+4,50 %

+6,36 %

+9,35 %

+4,00 %

-18,75 %

+40,96 %

-26,88 %

-26,88 %

-33,71 %

ISIN:DE000A2P4LJ5WKN:A2P4LJ

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• 10J
• Max